The global self amplifying RNA vaccines market was valued at USD 6.56 Billion in 2025 driven by increasing investment in healthcare research and development across the globe. The market is anticipated to grow at a CAGR of 13.10% during the forecast period 2026-2035 to reach a value of USD 22.47 Billion by 2035.
Base Year
Historical Period
Forecast Period
The market is driven by the increasing number of self-amplifying RNA (saRNA) vaccine candidates to fight against various infectious and viral conditions.
The market is witnessing heavy investments by research institutes, biopharmaceutical companies, and governments, to explore wider applications of saRNA vaccines.
The increasing approvals by the regulatory authorities are playing a crucial role in market development, thereby, boosting market growth.
Compound Annual Growth Rate
13.1%
Value in USD Billion
2026-2035
*this image is indicative*
Self-amplifying RNA (saRNA) vaccines use a self-replicating RNA platform to generate immune responses in the body. RNA vaccines work by triggering the immune system to defend against specific pathogens, using messenger RNA instead of inactivated viruses. Self-amplifying RNA vaccines are a specialized type of RNA vaccine that allows the RNA to replicate within the host cells. This self-amplification process leads to a strong immune response and higher levels of protein production. saRNA vaccine produces enhanced immunogenicity, and lower doses are required due to its self-amplifying nature and rapid production. This continues to drive the development of saRNA vaccine technology.
FDA Clearances Being Instrumental in Rising Market Demand
The market growth is driven by the evolving regulatory landscape that is allowing high-efficacy vaccines and medications in the market to address unmet needs for a wider section of the population. For instance, in April 2024, Ractigen Therapeutics, a pioneer in small activating RNA (saRNA) therapeutic development, received approval from the U.S. Food and Drug Administration for its Investigational New Drug application concerning RAG-01. This innovative saRNA treatment is expected to treat non-muscle invasive bladder cancer. This FDA approval is poised to commence clinical trials in several other regions along with the United States, bolstering market growth as regulatory approvals and clinical trials play a vital role in adding credibility to new drugs.
Additionally, the world’s first saRNA vaccine ARCT-154 was approved by the Japanese regulatory authorities in Japan in November 2023. This approval has given access to a new weapon to healthcare providers, through which the prevention of infectious diseases, and management of chronic diseases such as cancer will be made easier than ever. This approval marked a significant milestone as the first saRNA vaccine to be registered in the world.
The market is witnessing several trends and developments to improve the global current scenario. Some of the notable trends are as follows:
| Key Trends | Impact |
| Technological Advancements | The market is witnessing technological advancements in the diagnostic domain. Innovations in lipid nanoparticle delivery systems are playing a crucial role in market development as they enable stability and enhance efficacy along with the safety profile of vaccinations. |
| Rising focus on Next-Generation Vaccines | The growing interest in next-generation vaccines, including saRNA vaccines, is driving extensive research and development activities, collectively exploring wider applications for saRNA in other domains, boosting market demand and development. |
| Increasing Investment and Funding | The key players in the healthcare domain, government and healthcare institutions are investing to support the development of saRNA vaccines and bring effective treatments for viruses and infectious conditions. |
| Increasing Adoption Post COVID-19 Outbreak | The market is witnessing a rising number of saRNA vaccine candidates being developed for various infectious diseases, including COVID-19, influenza, and other viral infections. |
The EMR’s report titled “Self Amplifying RNA Vaccines Market Report and Forecast 2026-2035” offers a detailed analysis of the market based on the following segments:
Market Breakup by Route of Administration
Market Breakup by Application
Market Breakup by Region
Market Segmentation Based on Application to Witness Significant Growth
Based on application, the market report includes influenza, rabies, HIV-1, COVID-19, respiratory syncytial virus (RSV), and Ebola, among others. Historically, the COVID-19 segment has had a significant share of the market, driven by the advent of an unforeseen pandemic which triggered an urgent demand for effective vaccines, and led to the quick development of RNA-based vaccines globally. The market segment is backed by heavy investments by the government and several key players in the market.
Based on region, the market is divided into North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. Out of these, North America is the leading market due to the presence of global players in the region. The market dominance can be attributed to factors technical innovations as well as product launches.
Europe, with the presence of prominent academic institutions, holds a significant market share. In addition, the Asia Pacific region is expected to witness substantial growth in the forecast period. The rapid growth can be attributed to rising investments in improving the healthcare infrastructure to boost research and development initiatives related to the market. Countries like India, Japan and China are expected to emerge as key regional players in the Asia Pacific market.
The key features of the market report comprise patent analysis, clinical trials analysis, grants analysis, funding and investment analysis along with strategic initiatives by the leading players. The major companies in the market are as follows:
Pfizer is a global leader in developing and producing vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company played a pivotal role in the COVID-19 pandemic. The company partnered with BioNTech to study and develop COVID-19 mRNA vaccine candidates during the pandemic and delivered millions of vaccines.
The company is headquartered in Pune, India. Gennova is a biotechnology company focused on the research, development, production, and commercialization of bio-therapeutics and vaccines to address life-threatening diseases across various indications.
It is an American RNA medicines biotechnology company focused on finding, developing, and delivering treatments for rare diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA (siRNA), messenger RNA (mRNA), gene editing RNA, DNA, antisense oligonucleotides, and microRNA.
VLP Therapeutics Japan, LLC specialises in developing innovative vaccines and therapeutics using their proprietary Virus-Like Particle (VLP) technology. Their portfolio includes cutting-edge vaccines for infectious diseases such as dengue fever, malaria, and COVID-19, aimed at providing effective and long-lasting immunity with enhanced safety profiles.
It is an Australian biotechnology company focused on the research, development, and commercialisation of products that treat and prevent serious human medical conditions. The company portfolio includes blood plasma derivatives, vaccines, antivenom, and cell culture reagents used in various medical and genetic research and manufacturing applications.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include TriLink BioTechnologies, ImmunityBio, Inc., Gritstone bio, Inc., and eTheRNA Immunotherapies NV.
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Route of Administration |
|
| Breakup by Application |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share